The ambitious pursuit of creating gene-edited human embryos is facing a harsh reality check. Within just a year of their launch, two high-profile startups aiming to pioneer the “designer baby” industry—Manhattan Genomics and Bootstrap Bio —have effectively ceased operations. Their sudden closures highlight the immense financial, ethical, and legal hurdles facing a field that seeks to rewrite the human genetic code.
The High Stakes of Germline Editing
To understand why these failures matter, one must distinguish between current gene therapy and the controversial goal of these startups.
- Current Gene Therapy: Targets specific cells in an existing patient to treat a disease (e.g., sickle cell anemia). These changes die with the patient.
- Germline Editing: Targets human embryos. These changes become part of the individual’s DNA and are passed down to all future generations.
This distinction is why the industry is so volatile. Beyond the technical risk of “off-target” edits—where DNA is accidentally changed in unintended ways—the ethical implications are massive. Critics fear that a technology intended to prevent disease will inevitably be used for “enhancement,” leading to a market for children selected for intelligence, strength, or appearance.
A Pattern of Instability: Manhattan Genomics and Bootstrap Bio
The downfall of these two companies stems from different, yet equally destabilizing, issues:
1. Manhattan Genomics: Internal Fractures
Manhattan Genomics (also known as Manhattan Project) collapsed after only four months of operation. The company’s end was marked by internal governance disputes and “cofounder conflict.”
While cofounder Cathy Tie has moved on to launch a new venture, Origin Genomics, her former partner Eriona Hysolli cited a lack of transparency regarding a Cayman Islands-based entity as a primary reason for their split. This internal friction suggests that even if the science is sound, the complex legal and corporate structures required for such sensitive research can create insurmountable friction.
2. Bootstrap Bio: Financial and Legal Turbulence
Bootstrap Bio faced a more chaotic exit. CEO Chase Denecke cited a lack of investor interest as the primary reason the company ran out of capital, despite promising lab results.
However, the company was also hit by severe legal scandal. Its former Chief Science Officer, Qichen Yuan, was arrested on federal charges related to attempted sex trafficking. While the CEO claimed ignorance of these charges until after operations ceased, the incident underscores the high level of scrutiny and risk associated with recruiting talent in the highly specialized biotech sector.
The Shadow of the Past and the Future of the Industry
The industry operates under the long shadow of the 2018 He Jiankui scandal, where a Chinese scientist illegally edited embryos, leading to the birth of the world’s first gene-edited children and his subsequent imprisonment. This event established a global taboo that biotech entrepreneurs are now attempting to navigate.
Despite these setbacks, the appetite for funding remains. A third player, Preventive, recently emerged with $30 million in backing from high-profile tech figures, including Coinbase CEO Brian Armstrong and OpenAI CEO Sam Altman.
The collapse of these early startups suggests that while the scientific ambition to prevent genetic disease is high, the path to a commercially viable and ethically stable “designer baby” business is fraught with extreme financial, legal, and interpersonal risks.
Conclusion: The rapid failure of these first-wave startups demonstrates that technical capability is only one part of the equation; without stable governance, massive capital, and a clear ethical framework, the dream of germline editing remains highly unstable.
